Regarding a Report Concerning Sumitomo Pharma (The Company's Views on the GCR August 7 Report)
Filed with TSE · · 1 page · English
Summary by 6ix AI
The company rejects the assertions made in the report, stating they are based on unilateral views and are unacceptable. Sumitomo Pharma emphasizes the reliability of the materials submitted for regulatory review of AMCHEPRY® and its ongoing post-marketing clinical study. The company plans to take appropriate actions, including legal measures, against misleading information to protect its interests and those of its shareholders.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Sumitomo Pharma Co.Ltd. on 6ix
Story so far
Earlier from Sumitomo Pharma Co.Ltd
- Additional Explanation Regarding the Report “Sumitomo Chemical and Sumitomo Pharmaceutical: The 116 billion yen Swiss Shuffle”
- Regarding a Report Concerning Sumitomo Pharma
- Presentation Material (Conference on Q1 FY2026 Financial Results)
- Matters Concerning Controlling Shareholders, Etc.
- Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026
Later from Sumitomo Pharma Co.Ltd
- Notice Concerning Gain on Return of Retirement Benefit Trust (Extraordinary Income) Recorded in the Company’s Non-Consolidated Financial Statements
- Presentation Material (Conference on Q2 FY2026 Financial Results
- Sumitomo Pharma Announces Revision of Its Year-End Dividend Forecast for the Fiscal Year Ending March 31, 2027
- Sumitomo Pharma Announces Variances Between H1 FY2026 Financial Forecasts and Actual Results and Revisions to FY2026 Financial Forecasts
- Summary of Consolidated Financial Results for the Six Months Ended September 30, 2026 [IFRS]
Follow Sumitomo Pharma Co.Ltd into a list and get an email when it puts out news.
Follow Sumitomo Pharma Co.Ltd